CVRx has announced that the American Medical Association (AMA) has accepted new current procedural terminology (CPT) Category I codes for a baroreflex activation therapy, known as Barostim, to treat ...

MINNEAPOLIS, Dec. 26, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today that the U.S. Food and Drug Administration (FDA) has ...

Hackensack University Medical Center has successfully implanted a heart failure neuromodulation device, BAROSTIM NEO from Minneapolis-based CVRx Inc. The hospital is the first in the nation to use the ...

MINNEAPOLIS, CVRx, Inc., a private medical device company, announced that positive results from the 'Barostim Therapy for Heart Failure' randomized, controlled clinical trial were presented at the ...

Minneapolis-based medical device maker CVRx, has raised $93 million and taken on an additional $20 million in debt to complete a clinical trial for its Barostim Neo, a proprietary implantable device ...

MINNEAPOLIS, CVRx, a global medical device company, today announced that the first two patients have been treated with the BAROSTIM NEO ® System in the BaroreflexActivation Therapy for Heart Failure ...

CVRx's flagship product, the Barostim therapy, has been gaining attention in the medical community due to its innovative approach to treating heart failure. The company has been actively working to ...

MINNEAPOLIS, Nov. 18, 2020 (GLOBE NEWSWIRE) -- CVRx, Inc., developer of FDA-approved Barostim Therapy to treat chronic heart failure (HF), announced a CFO transition as part of the company’s long-term ...

CVRx, Inc., a private medical device company, announced that positive results from the 'Barostim Therapy for Heart Failure' randomized, controlled clinical trial were presented at the 2015 annual ...

MINNEAPOLIS, Oct. 18, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc (CVRX). (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today that the American Medical Association (AMA) CPT® ...